Премини към основното съдържание
Kesimpta

Please select your country (language)

Austria (Deutsch)

Belgium (Nederlands)

Denmark (Dansk)

France (Français)

Iceland (Islenska)

Lithuania (Lietuvių kalba)

Malta (Malti)

Portugal (Português)

Spain (Español)

Bulgaria (Български)

Croatia (Hrvatski)

Estonia (Eesti keel)

Germany (Deutsch)

Ireland (English)

Luxembourg (Français)

The Netherlands (Nederlands)

Romania (Română)

Sweden (Svenska)

Belgium (Français)

Cyprus (Ελληνικά)

Finland (suomi)

Greece (Ελληνικά)

Italy (Italiano)

Luxembourg (German)

Norway (Norsk)

Slovakia (Slovenčina)

UK-Northern Ireland (English)
 

Belgium (Deutsch)

Czech Republic (Česky)

Finland (Svenska)

Hungary (Magyar)

Latvia (Latviešu valoda)

Malta (English)

Poland (Polski)

Slovenia (slovenščina)

legal-bulgaria
  • Условия за ползване
  • Политика относно бисквитките
  • Настройки за бисквитки
© 2025 Novartis BG2204216287 април 2022

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Please refer to the Package Leaflet for more information.